Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 8 min read

Retatrutide: sourcing, documentation and price

Retatrutide (LY3437943) is an investigational GLP-1/GIP/glucagon triple receptor agonist. This page covers its identifiers, the research record across animal and clinical studies, and what laboratory buyers should expect

peptides-pro Editorial

Retatrutide, also known by the development code LY3437943, is an investigational triple receptor agonist acting at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. It is not an approved medicine in any jurisdiction; every study listed on this page describes it as investigational. The evidence block used for this article does not supply a sequence, molecular formula or molecular weight, so none are stated here. Buyers sourcing Retatrutide for laboratory work should treat the compound as a research reagent with an active clinical development programme behind it, not as a finished pharmaceutical.

The work centres on the GLP-1, GIP and glucagon receptor families, engaged simultaneously by a single peptide. That triple-receptor mechanism is the reason the compound appears in metabolic, hepatic and glycaemic research rather than in a single therapeutic area.

Research Studies

Retatrutide and body weight in diet-induced obese mouse and hamster models

In diet-induced obese MASH mouse and hamster models, retatrutide was evaluated for efficacy as a triple glucagon, GIP and GLP-1 receptor agonist [2]. In mice, the compound reduced body weight by 31% (p < 0.0001 versus vehicle), with reductions in both fat and lean mass and in food and water intake during the first days of treatment; energy expenditure was not significantly altered [2]. The same study reported marked reductions in the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides and total cholesterol content [2]. Effects in hamsters were also reported, though the available excerpt is truncated [2]. These are animal findings and do not establish human outcomes.

Retatrutide and hepatic steatosis in diet-induced obese MASH models

The hepatic endpoints in the mouse and hamster work are worth separating from the weight endpoints. Retatrutide markedly reduced hepatic steatosis score in the mouse model, alongside reductions in fatty acids, triglycerides and total cholesterol content [2]. The models used were diet-induced obese MASH mouse and hamster models, described by the authors as two preclinical models routinely used for assessing new therapies targeting obesity [2]. No human hepatic endpoint appears in the evidence block.

Retatrutide and insulin resistance markers in diet-induced obese mice

Retatrutide markedly reduced the HOMA-IR index of insulin resistance in diet-induced obese mice [2]. HOMA-IR is a calculated index rather than a direct clamp measurement, and the finding is confined to that animal model. Human glycaemic work is described separately below and uses different endpoints.

Retatrutide and glycaemic control in adults with type 2 diabetes mellitus

Two registered studies examine glycaemic parameters in adults with type 2 diabetes mellitus. One measures the effect of weekly retatrutide versus placebo on time to recovery from hypoglycaemia during a hypoglycaemic clamp after 16 weeks of treatment [5]. The other compares retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment, with the primary objective framed as the effect on insulin secretion and insulin sensitivity [6]. Both are registered protocols; the evidence block does not report results.

Retatrutide and body weight reduction in adults with obesity or overweight

A registered study evaluates the efficacy and safety of retatrutide compared with placebo for body weight reduction in participants with obesity or overweight, with participation lasting about 65 weeks and possibly including about 18 visits [4]. A separate registered study investigates different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight, with participation lasting about 113 weeks [3]. Neither entry in the evidence block reports outcomes.

Retatrutide and maintenance of weight reduction in individuals with obesity

One registered study is designed around maintenance rather than induction of weight loss. It has an 80-week lead-in phase in which all participants take retatrutide dose 1, followed by a 36-week randomised, double-blinded phase in which participants take retatrutide dose 1, retatrutide dose 2, or switch to placebo; total participation is around 125 weeks [8]. The stated purpose is to learn more about how retatrutide maintains body weight loss [8].

Retatrutide and chronic low back pain in participants with obesity or overweight

A registered study evaluates the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight, with participation lasting about 80 weeks [7]. This is a pain endpoint rather than a weight endpoint, and it sits outside the metabolic framing of the other registered protocols. No results are reported in the evidence block.

Retatrutide and pre-approval expanded access in severe obesity

An expanded access programme provides pre-approval single-patient access to retatrutide for adults with severe obesity, defined as a body mass index of 35 kg/m² or greater with at least two serious or life-threatening obesity-related complications, who are refractory to the best approved therapy and unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine [1]. Expanded access is not a trial and does not generate the same controlled data; it is included here because it defines the population the sponsor considers most in need of pre-approval access.

Retatrutide and receptor co-agonism in obese rodents

Related receptor-level work reports that functional co- and tri-agonists at the GLP-1, GIP and glucagon receptors effectively decrease body weight and hyperglycaemia, but are associated with adverse gastrointestinal effects related to GLP-1R agonism, and describes the discovery that obesity can be reversed in the absence of a functional receptor in obese rodents [9]. That finding concerns co-agonism as a class rather than retatrutide specifically, and it is included as background to the triple-receptor mechanism.

Comparing the registered protocols

The table below sets out the registered studies in the evidence block by population and stated purpose. Durations are as stated in each registry entry.

Registry entryPopulationStated purposeDuration
NCT07357415 [3]Adults without type 2 diabetes who have obesity or overweightEfficacy and safety of different dose escalation schemesAbout 113 weeks
NCT07232719 [4]Adults with obesity or overweightEfficacy and safety versus placebo for body weight reductionAbout 65 weeks
NCT06982846 [5]Adults with type 2 diabetes mellitusTime to recovery from hypoglycaemia during hypoglycaemic clamp16 weeks of treatment
NCT06982859 [6]Adults with type 2 diabetes mellitusTotal clamp disposition index (cDI)28 weeks of treatment
NCT07035093 [7]Adults with obesity or overweight and chronic low back painRelief of chronic low back painAbout 80 weeks
NCT06859268 [8]Individuals with obesityMaintenance of body weight lossAbout 125 weeks
NCT07629401 [1]Adults with BMI ≥35 kg/m² and ≥2 serious obesity-related complicationsPre-approval single-patient expanded accessNot stated

What the evidence does and does not cover

Two categories of evidence appear above, and they should not be read as equivalent. The animal work reports quantified outcomes in diet-induced obese MASH mouse and hamster models, including a 31% body weight reduction in mice and reductions in hepatic and lipid parameters [2]. The registered studies report designs, populations, endpoints and durations, but the evidence block contains no results from them [1][3][4][5][6][7][8]. The receptor co-agonism paper is background on the mechanism class rather than on this compound [9].

Nothing in the evidence block supports a statement about human efficacy, human dosing, or the magnitude of any effect in people. Where a figure is given, it belongs to the model named alongside it.

Sourcing and documentation

Because retatrutide remains investigational, a laboratory buyer should expect the documentation package to reflect a research reagent rather than a licensed product. In practical terms that means a certificate of analysis covering identity and purity for the specific lot, and a specification sheet stating the form supplied. The evidence block does not describe storage conditions, solubility, salt form or purity grades for retatrutide, so no such values are asserted here. Buyers should request the lot-specific documents from the supplier rather than relying on a generic product page.

It is also worth noting what the registry entries imply about the compound's status. Every study cited describes retatrutide as investigational, and one of them exists specifically to provide pre-approval access to patients who cannot enter a trial [1]. That is a useful signal for procurement: the material is not a discontinued or abandoned candidate, and the research literature around it is active.

Price

The evidence block contains no pricing information for retatrutide, and no price is stated on this page. Price for a research peptide depends on the lot size, the purity grade, the documentation supplied with the lot, and the supplier's own quality-control overhead, none of which are fixed by the evidence available here. Buyers comparing suppliers should compare the documentation package first and the headline price second, because a certificate of analysis that does not match the lot being shipped is worth nothing regardless of cost.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound like retatrutide for themselves should speak to a licensed clinician rather than treating a research catalogue as a source of advice.

Sources

WhatsApp